To assess the Effect of administration of 2 formulation of AZD3241 on blood concentration in healthy volunteers

Study identifier:D0490C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) after Administration of Multiple Doses in Healthy Male and Female Volunteers

Medical condition

Parkinson's disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3241 ER formulation 1, Placebo, AZD3241 Alternative titration scheme with formulation 1 or 2

Sex

All

Actual Enrollment

24

Study type

Interventional

Age

30 Years - 65 Years

Date

Study Start Date: 01 Nov 2011
Primary Completion Date: 01 Dec 2011
Study Completion Date: 01 Dec 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Aug 2012 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria